Orexo AB (publ) Price & Performance (ORXOF)

Orexo AB has revealed significant changes to its board of directors, following its annual general meeting. The company aims to strengthen governance amid ongoing financial challenges and a shifting pharmaceutical landscape. These leadership adjustments are designed to support Orexo’s strategic focus on expanding its product pipeline and operational efficiency.12

Orexo AB reported Q1 2025 revenues of SEK 146 million, reflecting a modest year-over-year increase. The company maintained positive EBITDA but faced pressures from currency fluctuations and lower royalties. Subsol, its main U.S. product, remained the primary revenue driver, while cash flow from operations showed improvement compared to last year.34

Orexo AB’s stock has declined for three consecutive days, closing at SEK 14.42. Technical indicators point to a continued downward trend in the near term, with forecasts suggesting further weakness. Increased trading volume on falling prices signals caution, and analysts recommend a negative stance until new support levels are established.56